Clinical Trials

870 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04165317 2026-01-22

CREST

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03711032 2025-12-22

MK-3475-676

1,397 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03528694 2025-11-25

POTOMAC

1,018 enrolled

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07064863 2025-07-17

BCG-TIME

31 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT05037279 2025-02-20

EVER

Phase 3 Recruiting

540 enrolled

Urinary Bladder Neoplasms, Recurrence

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

120 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04806178 2024-12-09

IMMUNOBCG

30 enrolled

Urinary Bladder Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Phase 3 Terminated

41 enrolled

Urinary Bladder Neoplasms

NCT02948543 2023-06-18

BCG+MM

Phase 3 Unknown

501 enrolled

Urinary Bladder Neoplasms

NCT05701332 2023-01-27

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Phase 4 Unknown

25 enrolled

Fibrosis, Oligospermia

NCT00070070 2022-10-12

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

6 enrolled 7 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01838200 2022-10-12

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

Phase 1 Terminated

5 enrolled 12 charts

Dermatologic

Melanoma

NCT02792192 2021-10-28

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Phase 1/2 Terminated

24 enrolled 18 charts

Urinary Bladder Neoplasms

NCT00694915 2021-08-17

STCC

122 enrolled

Urinary Bladder Neoplasms

NCT02010203 2020-02-17

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Phase 1/2 Terminated

104 enrolled 21 charts

Urinary Bladder Neoplasms, Neoplasms

NCT01373294 2019-08-06

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

17 enrolled 8 charts

Urinary Bladder Neoplasms

NCT00974818 2015-11-20

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Phase 3 Terminated

50 enrolled 7 charts

Urinary Bladder Neoplasms

NCT01498172 2015-02-04

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

23 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01284205 2014-08-29

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Phase 3 Withdrawn

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00007826 2013-09-20

Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00427570 2013-06-24

Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00002990 2013-06-12

Surgery and BCG in Treating Patients With Bladder Cancer

1,288 enrolled

Urinary Bladder Neoplasms

NCT00016133 2013-05-30

Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery

Phase 1/2 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00003386 2013-04-11

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Phase 2 Terminated

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00003184 2013-04-04

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Breast

Breast Neoplasms

NCT00004122 2013-02-01

BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer

Urinary Bladder Neoplasms

NCT00003759 2013-01-31

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

Urinary Bladder Neoplasms

NCT00003023 2013-01-18

Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer

24 enrolled

CNSSarcoma

Neuroblastoma, Sarcoma, Osteosarcoma

NCT00023842 2012-09-24

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

97 enrolled

Urinary Bladder Neoplasms

NCT00514072 2012-08-09

Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer

Phase 2 Unknown

54 enrolled

Prostatic Neoplasms

NCT00006352 2012-07-18

Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer

453 enrolled

Thoracic

Lung Neoplasms

NCT00003279 2012-03-06

SILVA

500 enrolled

Thoracic

Lung Neoplasms

NCT01442519 2011-09-28

BCG/EMDA-MMC

212 enrolled

Urinary Bladder Neoplasms

NCT00330707 2011-03-04

Combined Use of BCG and Interferon Alpha in Bladder Cancer

Phase 2/3 Completed

140 enrolled